Oxidative Stress in Neurodegenerative Diseases

Molecular Neurobiology

Volumn 53, Issue 6, 2016, Pages 4094-4125

  Niedzielska, Ewa ^a   Smaga, Irena ^a   Gawlik, Maciej ^a   Moniczewski, Andrzej ^a   Stankowicz, Piotr ^a   Pera, Joanna ^b   Filip, Małgorzata ^a,c  

^a JAGIELLONIAN UNIVERSITY   (Poland)

^b JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Alzheimer s disease; Amyotrophic lateral sclerosis; Antioxidant defense molecule; ESR electron spin resonance; IST immuno spin trapping technique; Non enzymatic and enzymatic antioxidant; Oxidative stress biomarker; Parkinson s disease

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANTIOXIDANT; ANTIPARKINSON AGENT; BIOLOGICAL MARKER; CHOLINESTERASE INHIBITOR; CREATINE; DONEPEZIL; MEMANTINE; NORPHENAZONE; REACTIVE OXYGEN METABOLITE; RILUZOLE; RIVASTIGMINE; UBIDECARENONE; ZONISAMIDE;

ADD ON THERAPY; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; ANTIOXIDANT ACTIVITY; DEGENERATIVE DISEASE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE MARKER; DRUG EFFECT; DRUG MECHANISM; HUMAN; ICD-10; MOLECULAR PATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PARKINSON DISEASE; REVIEW; ANIMAL; CLINICAL TRIAL (TOPIC); METABOLISM; PATHOLOGY;

ANIMALS; ANTIOXIDANTS; BIOMARKERS; CLINICAL TRIALS AS TOPIC; HUMANS; NEURODEGENERATIVE DISEASES; OXIDATIVE STRESS;

EID: 84937675316     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-015-9337-5     Document Type: Review

References (283)

1. Li J, O W, Li W, Jiang Z, Ghanbari HA (2013) Oxidative stress and neurodegenerative disorders. Int J Mol Sci 14:24438–24475
2. Falkowski PG, Godfrey LV (2008) Electrons, life and the evolution of earth’s oxygen cycle. Philosophical Transactions of the Royal Society of London Ser B, Biol Sci 363:2705–2716
3. Paiva CN, Bozza MT (2014) Are reactive oxygen species always detrimental to pathogens? Antioxid Redox Signal 20:1000–1037
4. Popa-Wagner A, Mitran S, Sivanesan S, Chang E, Buga A (2013) ROS and brain diseases: the good, the bad, and the ugly. Oxidative Med Cell Longevity 2013
5. Metodiewa D, KoÅ›ka C (2000) Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxic events and neurologic disorders. An overview. Neurotox Res 1:197–233
6. Venditti P, Di Stefano L, Di Meo S (2013) Mitochondrial metabolism of reactive oxygen species. Mitochondrion 13:71–82
7. Li X, Fang P, Mai J, Choi ET, Wang H, Yang X (2013) Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers. J Hematol Oncol 6
8. Mailloux RJ, McBride SL, Harper M (2013) Unearthing the secrets of mitochondrial ROS and glutathione in bioenergetics. Trends Biochem Sci 38:592–602
9. Cordeiro RM (2014) Reactive oxygen species at phospholipid bilayers: distribution, mobility and permeation. Biochim Biophys Acta 1838:438–444
10. Blough NV, Zafiriou OC (1985) Reaction of superoxide with nitric oxide to form peroxonitrite in alkaline aqueous solution. Inorg Chem 24:3502–3504
11. Forstermann U, Sessa WC (2012) Nitric oxide synthases: regulation and function. Eur Heart J 33:829–837
12. Bedard K, Krause K (2007) The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev 87:245–313
13. Fritz KS, Petersen DR (2013) An overview of the chemistry and biology of reactive aldehydes. Free Radic Biol Med 59:85–91
14. Albarracin SL, Stab B, Casas Z, Sutachan JJ, Samudio I, Gonzalez J, Gonzalo L, Capani F, Morales L, Barreto GE (2012) Effects of natural antioxidants in neurodegenerative disease. Nutr Neurosci 15:1–9
15. Pinchuk I, Shoval H, Dotan Y, Lichtenberg D (2012) Evaluation of antioxidants: scope, limitations and relevance of assays. Chem Phys Lipids 165:638–647
16. Miller E, bieta, Morel A, Saso L, Saluk J (2014) Isoprostanes and neuroprostanes as biomarkers of oxidative stress in neurodegenerative diseases. Oxidat Med Cell Longevity 2014
17. Ho E, Karimi Galougahi K, Liu C, Bhindi R, Figtree GA (2013) Biological markers of oxidative stress: applications to cardiovascular research and practice. Redox Biol 1:483–491
18. Zitka O, Krizkova S, Skalickova S, Kopel P, Babula P, Adam V, Kizek R (2013) Electrochemical study of DNA damaged by oxidation stress. Comb Chem High Throughput Screen 16:130–141
19. Li J, Liu D, Sun L, Lu Y, Zhang Z (2012) Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J Neurol Sci 317:1–5
20. Yavuz BB, Yavuz B, Halil M, Cankurtaran M, Ulger Z, Cankurtaran ES, Aytemir K, Ariogul S (2008) Serum elevated gamma glutamyltransferase levels may be a marker for oxidative stress in Alzheimer’s disease. Int Psychogeriatr 20:815–823
21. Kadiiska MB, Basu S, Brot N, Cooper C, Saari Csallany A, Davies MJ, George MM, Murray DM, Jackson Roberts L IIL, Shigenaga MK, Sohal RS, Stocker R, Van Thiel DH, Wiswedel I, Hatch GE, Mason RP (2013) Biomarkers of oxidative stress study V: ozone exposure of rats and its effect on lipids, proteins, and DNA in plasma and urine. Free Radic Biol Med 61:408–415
22. Gomez-Mejiba SE, Zhai Z, Della-Vedova MC, Muñoz MD, Chatterjee S, Towner RA, Hensley K, Floyd RA, Mason RP, Ramirez DC (2014) Immuno-spin trapping from biochemistry to medicine: advances, challenges, and pitfalls. focus on protein-centered radicals. Biochim Biophys Acta - Gen Subj 1840:722–729
23. Cozzolino M, Carrì MT (2012) Mitochondrial dysfunction in ALS. Prog Neurobiol 97:54–66
24. Chen S, Sayana P, Zhang X, Le W (2013) Genetics of amyotrophic lateral sclerosis: an update. Molec Neurodegen 8
25. Weiduschat N, Mao X, Hupf J, Armstrong N, Kang G, Lange DJ, Mitsumoto H, Shungu DC (2014) Motor cortex glutathione deficit in ALS measured in vivo with the J-editing technique. Neurosci Lett 570:102–107
26. Parakh S, Spencer DM, Halloran MA, Soo KY, Atkin JD (2013) Redox regulation in amyotrophic lateral sclerosis. Oxidat Med Cell Longevity
27. Blokhuis AM, Groen EJN, Koppers M, Van Den Berg LH, Pasterkamp RJ (2013) Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol 125:777–794
28. Schymick JC, Talbot K, Traynor BJ (2007) Genetics of sporadic amyotrophic lateral sclerosis. Hum Mol Genet 16:R233–R242
29. Corcia P, Blasco H, Camu W (2014) Genetics of amyotrophic lateral sclerosis. Presse Med 43:555–562
30. Mendez EF, Sattler R (2015) Biomarker development for C9orf72 repeat expansion in ALS. Brain Res 1607:26–35
31. Beckman G, Lundgren E, Tarnvik A (1973) Superoxide dismutase isozymes in different human tissues, their genetic control and intracellular localization. Hum Hered 23:338–345
32. Saccon RA, Bunton-Stasyshyn RKA, Fisher EMC, Fratta P (2013) Is SOD1 loss of function involved in amyotrophic lateral sclerosis? Brain 136:2342–2358
33. Pasinelli P, Belford ME, Lennon N, Bacskai BJ, Hyman BT, Trotti D, Brown RH Jr (2004) Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and aggregate with Bcl-2 in spinal cord mitochondria. Neuron 43:19–30
34. Rakhit R, Crow JP, Lepock JR, Kondejewski LH, Cashman NR, Chakrabartty A (2004) Monomeric Cu, Zn-superoxide dismutase is a common misfolding intermediate in the oxidation models of sporadic and familial amyotrophic lateral sclerosis. J Biol Chem 279:15499–15504
35. Ezzi SA, Urushitani M, Julien J (2007) Wild-type superoxide dismutase acquires binding and toxic properties of ALS-linked mutant forms through oxidation. J Neurochem 102:170–178
36. Ito H, Wate R, Zhang J, Ohnishi S, Kaneko S, Ito H, Nakano S, Kusaka H (2008) Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 213:448–455
37. Watanabe M, Dykes-Hoberg M, Cizewski Culotta V, Price DL, Wong PC, Rothstein JD (2001) Histological evidence of protein aggregation in mutant SOD1 transgenic mice and in amyotrophic lateral sclerosis neural tissues. Neurobiol Dis 8:933–941
38. Forsberg K, Jonsson PA, Andersen PM, Bergemalm D, Graffmo KS, Hultdin M, Jacobsson J, Rosquist R, Marklund SL, Brännström T (2010) Novel antibodies reveal inclusions containing non-native SOD1 in sporadic ALS patients. PLoS ONE 5
39. Tohgi H, Abe T, Yamizaki K, Murata T, Ishizaki E, Isobe C (1999) Remarkable increase in cerebrospinal fluid 3-nitrotyrosine in patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 46:129–131
40. Smith RG, Henry YK, Mattson MP, Appel SH (1998) Presence of 4-hydroxynonenal in cerebrospinal fluid of patients with sporadic amyotrophic lateral sclerosis. Ann Neurol 44:696–699
41. Bogdanov M, Brown RH Jr, Matson W, Smart R, Hayden D, O’Donnell H, Flint Beal M, Cudkowicz M (2000) Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med 29:652–658
42. Ihara Y, Nobukuni K, Takata H, Hayabara T (2005) Oxidative stress and metal content in blood and cerebrospinal fluid of amyotrophic lateral sclerosis patients with and without a Cu, Zn-superoxide dismutase mutation. Neurol Res 27:105–108
43. Barber SC, Shaw PJ (2010) Oxidative stress in ALS: key role in motor neuron injury and therapeutic target. Free Radic Biol Med 48:629–641
44. Oteiza PI, Uchitel OD, Carrasquedo F, Dubrovski AL, Roma JC, Fraga CG (1997) Evaluation of antioxidants, protein, and lipid oxidation products in blood from sporadic amiotrophic lateral sclerosis patients. Neurochem Res 22:535–539
45. Babu GN, Kumar A, Chandra R, Puri SK, Singh RL, Kalita J, Misra UK (2008) Oxidant-antioxidant imbalance in the erythrocytes of sporadic amyotrophic lateral sclerosis patients correlates with the progression of disease. Neurochem Int 52:1284–1289
46. LoGerfo A, Chico L, Borgia L, et al. (2014) Lack of association between nuclear factor erythroid-derived 2-like 2 promoter gene polymorphisms and oxidative stress biomarkers in amyotrophic lateral sclerosis patients. Oxidat Med Cell Longevity, vol. 2014, Article ID 432626, 9 pages, 2014. doi:10.1155/2014/432626
47. Mitsumoto H, Santella R, Liu X, Bogdanov M, Zipprich J, Wu H, Mahata J, Kilty M, Bednarz K, Bell D, Gordon PH, Hornig M, Mehrazin M, Naini A, Flint Beal M, Factor-Litvak P (2008) Oxidative stress biomarkers in sporadic ALS. Amyotrophic Lat Scler 9:177–183
48. Ikawa M, Okazawa H, Tsujikawa T, Muramatsu T, Kishitani T, Kamisawa T, Matsunaga A, Yamamura O, Mori T, Hamano T, Kiyono Y, Nakamoto Y, Yoneda M (2014) Increased cerebral oxidative stress in amyotrophic lateral sclerosis: a 62CU-ATSM pet study. Neurology 82
49. Tohgi H, Abe T, Yamazaki K, Murata T, Ishizaki E, Isobe C (1999) Increase in oxidized NO products and reduction in oxidized glutathione in cerebrospinal fluid from patients with sporadic form of amyotrophic lateral sclerosis. Neurosci Lett 260:204–206
50. Boll M, Alcaraz-Zubeldia M, Montes S, Murillo-Bonilla L, Rios C (2003) Raised nitrate concentration and low SOD activity in the CSF of sporadic ALS patients. Neurochem Res 28:699–703
51. Nikolic-Kokic A, Stevic Z, Blagojevic D, Davidovic B, Jones DR, Spasic MB (2006) Alterations in anti-oxidative defence enzymes in erythrocytes from sporadic amyotrophic lateral sclerosis (SALS) and familial ALS patients. Clin Chem Lab Med 44:589–593
52. Apostolski S, Marinkovic Z, Nikolic A, Blagojevic D, Spasic MB, Michael Michelson A (1998) Glutathione peroxidase in amyotrophic lateral sclerosis: the effects of selenium supplementation. J Environ Pathol Toxicol Oncol 17:325–329
53. Kokic AN, Stevic Z, Stojanovic S, Blagojevic DP, Jones DR, Pavlovic S, Niketic V, Apostolski S, Spasic MB (2005) Biotransformation of nitric oxide in the cerebrospinal fluid of amyotrophic lateral sclerosis patients. Redox Rep 10:265–270
54. Süssmuth SD, Brettschneider J, Ludolph AC, Tumani H (2008) Biochemical markers in CSF of ALS patients. Curr Med Chem 15:1788–1801
55. Tanaka H, Shimazawa M, Takata M, Kaneko H, Tsuruma K, Ikeda T, Warita H, Aoki M, Yamada M, Takahashi H, Hozumi I, Minatsu H, Inuzuka T, Hara H (2013) ITIH4 and Gpx3 are potential biomarkers for amyotrophic lateral sclerosis. J Neurol 260:1782–1797
56. Kuzma M, Jamrozik Z, Baranczyk-Kuzma A (2006) Activity and expression of glutathione S-transferase pi in patients with amyotrophic lateral sclerosis. Clin Chim Acta 364:217–221
57. Cova E, Bongioanni P, Cereda C, Metelli MR, Salvaneschi L, Bernuzzi S, Guareschi S, Rossi B, Ceroni M (2010) Time course of oxidant markers and antioxidant defenses in subgroups of amyotrophic lateral sclerosis patients. Neurochem Int 56:687–693
58. De Bustos F, Jiménez-Jiménez FJ, Molina JA, Esteban J, Guerrero-Sola A, Zurdo M, Ortì-Pareja M, Tallón-Barranco A, Gómez-Escalonilla C, Ramírez-Ramos C, Arenas J, Enríquez De Salamanca R (1998) Cerebrospinal fluid levels of alpha-tocopherol in amyotrophic lateral sclerosis. J Neural Transm 105:703–708
59. Paraskevas GP, Kapaki E, Libitaki G, Zournas C, Segditsa I, Papageorgiou C (1997) Ascorbate in healthy subjects, amyotrophic lateral sclerosis and Alzheimer’s disease. Acta Neurol Scand 96:88–90
60. Johnson WM, Wilson-Delfosse AL, Mieyal JJ (2012) Dysregulation of glutathione homeostasis in neurodegenerative diseases. Nutrients 4:1399–1440
61. Desnuelle C, Dib M, Garrel C, Favier A (2001) A double-blind, placeho-controlled randomized clinical trial of a-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. Amyotrop Lateral Sclerosis Motor Neuron Disord 2:9–18
62. Graf M, Ecker D, Horowski R, Kramer B, Riederer P, Gerlach M, Hager C, Ludolph AC (2005) High dose vitamin E therapy in amyotrophic lateral sclerosis as add-on therapy to riluzole: results of a placebo-controlled double-blind study. J Neural Transm 112:649–660
63. Veldink JH, Kalmijn S, Groeneveld G, Wunderink W, Koster A, De Vries JHM, Van Der Luyt J, Wokke JHJ, Van Den Berg LH (2007) Intake of polyunsaturated fatty acids and vitamin E reduces the risk of developing amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 78:367–371
64. Yoshino H, Kimura A (2006) Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotrop Later Sclerosis: Off Public World Fed Neurol Res Group Motor Neuron Dis 7:241–245
65. https://clinicaltrials.gov/show/NCT01492686. Accessed 15 May 2015
66. Kaufmann P, Thompson JLP, Levy G, Buchsbaum R, Shefner J, Krivickas LS, Katz J, Rollins Y, Barohn RJ, Jackson CE, Tiryaki E, Lomen-Hoerth C, Armon C, Tandan R, Rudnicki SA, Rezania K, Sufit R, Pestronk A, Novella SP, Heiman-Patterson T, Kasarskis EJ, Pioro EP, Montes J, Arbing R, Vecchio D, Barsdorf A, Mitsumoto H, Levin B (2009) Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann Neurol 66:235–244
67. Groeneveld GJ, Veldink JH, Van der Tweel I, Kalmijn S, Beijer C, De Visser M, Wokke JHJ, Franssen H, Van den Berg LH (2003) A randomized sequential trial of creatine in amyotrophic lateral sclerosis. Ann Neurol 53:437–445
68. Louwerse ES, Weverling GJ, Bossuyt PMM, Meyjes FEP, De Jong JMBV (1995) Randomized, double-blind, controlled trial of acetylcysteine in amyotrophic lateral sclerosis. Arch Neurol 52:559–564
69. Lange DJ, Murphy PL, Diamond B, Appel V, Lai EC, Younger DS, Appel SH (1998) Selegiline is ineffective in a collaborative double-blind, placebo-controlled trial for treatment of amyotrophic lateral sclerosis. Arch Neurol 55:93–96
70. Weishaupt JH, Bartels C, Pölking E, Dietrich J, Rohde G, Poeggeler B, Mertens N, Sperling S, Bohn M, Hüther G, Schneider A, Bach A, Sirén A, Hardeland R, Bähr M, Nave K, Ehrenreich H (2006) Reduced oxidative damage in ALS by high-dose enteral melatonin treatment. J Pineal Res 41:313–323
71. Zoccolella S., Santamato, A. Lamberti, P. (2009) Current and emerging treatments for amyotrophic lateral sclerosis. Neuropsychiat Dis Treatment Vol 5, Issue 1, 2009, Pages 577–595 5:577–595
72. Turner BJ, Talbot K (2008) Transgenics, toxicity and therapeutics in rodent models of mutant SOD1-mediated familial ALS. Prog Neurobiol 85:94–134
73. McGoldrick P, Joyce PI, Fisher EMC, Greensmith L (2013) Rodent models of amyotrophic lateral sclerosis. Biochim Biophys Acta (BBA) - Mol Basis Dis 1832:1421–1436
74. Bogdanov MB, Ramos LE, Xu Z, Beal MF (1998) Elevated ‘hydroxyl radical’ generation in vivo in an animal model of amyotrophic lateral sclerosis. J Neurochem 71:1321–1324
75. Liu D, Wen J, Liu J, Li L (1999) The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J 13:2318–2328
76. Towner RA, Smith N, Saunders D, Lupu F, Silasi-Mansat R, West M, Ramirez DC, Gomez-Mejiba SE, Bonini MG, Mason RP, Ehrenshaft M, Hensley K (2013) In vivo detection of free radicals using molecular MRI and immuno-spin trapping in a mouse model for amyotrophic lateral sclerosis. Free Radic Biol Med 63:351–360
77. Poon HF, Hensley K, Thongboonkerd V, Merchant ML, Lynn BC, Pierce WM, Klein JB, Calabrese V, Butterfield DA (2005) Redox proteomics analysis of oxidatively modified proteins in G93A-SOD1 transgenic mice—a model of familial amyotrophic lateral sclerosis. Free Radic Biol Med 39:453–462
78. Liu D, Bao F, Wen J, Liu J (2007) Mutation of superoxide dismutase elevates reactive species: comparison of nitration and oxidation of proteins in different brain regions of transgenic mice with amyotrophic lateral sclerosis. Neuroscience 146:255–264
79. Miana-Mena FJ, González-Mingot C, Larrodé P, Muñoz MJ, Oliván S, Fuentes-Broto L, Martínez-Ballarín E, Reiter RJ, Osta R, García JJ (2011) Monitoring systemic oxidative stress in an animal model of amyotrophic lateral sclerosis. J Neurol 258:762–769
80. Morimoto N, Miyazaki K, Kurata T, Ikeda Y, Matsuura T, Kang D, Ide T, Abe K (2012) Effect of mitochondrial transcription factor a overexpression on motor neurons in amyotrophic lateral sclerosis model mice. J Neurosci Res 90:1200–1208
81. Seo J, Baek I, Leem Y, Kim T, Cho Y, Lee SM, Park YH, Han P (2011) SK-PC-B70M alleviates neurologic symptoms in G93A-SOD1 amyotrophic lateral sclerosis mice. Brain Res 1368:299–307
82. Casoni F, Basso M, Massignan T, Gianazzail E, Cheroni C, Salmona M, Bendotti C, Bonetto V (2005) Protein nitration in a mouse model of familial amyotrophic lateral sclerosis: possible multifunctional role in the pathogenesis. J Biol Chem 280:16295–16304
83. Nardo G, Pozzi S, Mantovani S, Garbelli S, Marinou K, Basso M, Mora G, Bendotti C, Bonetto V (2009) Nitroproteomics of peripheral blood mononuclear cells from patients and a rat model of ALS. Antioxid Redox Signal 11:1559–1567
84. Basso M, Samengo G, Nardo G, Massignan T, D’Alessandro G, Tartari S, Cantoni L, Marino M, Cheroni C, de Biasi S, Giordana MT, Strong MJ, Estevez AG, Salmona M, Bendotti C, Bonetto V (2009) Characterization of detergent-insoluble proteins in ALS indicates a causal link between nitrative stress and aggregation in pathogenesis. PLoS ONE 4
85. Cha CI, Chung YH, Shin C, Shin DH, Kim YS, Gurney ME, Lee KW (2000) Immunocytochemical study on the distribution of nitrotyrosine in the brain of the transgenic mice expressing a human Cu/Zn SOD mutation. Brain Res 853:156–161
86. Tokuda E, Ono S, Ishige K, Watanabe S, Okawa E, Ito Y, Suzuki T (2008) Ammonium tetrathiomolybdate delays onset, prolongs survival, and slows progression of disease in a mouse model for amyotrophic lateral sclerosis. Exp Neurol 213:122–128
87. Chi L, Ke Y, Luo C, Gozal D, Liu R (2007) Depletion of reduced glutathione enhances motor neuron degeneration in vitro and in vivo. Neuroscience 144:991–1003
88. Vargas MR, Johnson DA, Johnson JA (2011) Decreased glutathione accelerates neurological deficit and mitochondrial pathology in familial ALS-linked hSOD1G93A mice model. Neurobiol Dis 43:543–551
89. Vargas MR, Johnson DA, Sirkis DW, Messing A, Johnson JA (2008) Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J Neurosci 28:13574–13581
90. Kato S, Kato M, Abe Y, Matsumura T, Nishino T, Aoki M, Itoyama Y, Asayama K, Awaya A, Hirano A, Ohama E (2005) Redox system expression in the motor neurons in amyotrophic lateral sclerosis (ALS): immunohistochemical studies on sporadic ALS, superoxide dismutase 1 (SOD1)-mutated familial ALS, and SOD1-mutated ALS animal models. Acta Neuropathol 110:101–112
91. Kato S, Saeki Y, Aoki M, Nagai M, Ishigaki A, Itoyama Y, Kato M, Asayama K, Awaya A, Hirano A, Ohama E (2004) Histological evidence of redox system breakdown caused by superoxide dismutase 1 (SOD1) aggregation is common to SOD1-mutated neurons in humans and animal models. Acta Neuropathol 107:149–158
92. Cudkowicz ME, Pastusza KA, Sapp PC, Mathews RK, Leahy J, Pasinelli P, Francis JW, Jiang D, Andersen JK, Brown RH Jr (2002) Survival in transgenic ALS mice does not vary with CNS glutathione peroxidase activity. Neurology 59:729–734
93. Lucchetti J, Marino M, Papa S, Tortarolo M, Guiso G, Pozzi S, Bonetto V, Caccia S, Beghi E, Bendotti C, Gobbi M (2013) A mouse model of familial ALS has increased CNS levels of endogenous Ubiquinol9/10 and does not benefit from exogenous administration of Ubiquinol10. PLoS ONE 8
94. Klivenyi P, Kiaei M, Gardian G, Calingasan NY, Beal MF (2004) Additive neuroprotective effects of creatine and cyclooxygenase 2 inhibitors in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurochem 88:576–582
95. Peña-Altamira E, Crochemore C, Virgili M, Contestabile A (2005) Neurochemical correlates of differential neuroprotection by long-term dietary creatine supplementation. Brain Res 1058:183–188
96. Zhang W, Narayanan M, Friedlander RM (2003) Additive neuroprotective effects of minocycline with creatine in a mouse model of ALS. Ann Neurol 53:267–270
97. Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-Daouk R, Beal MF (1999) Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp Neurol 157:142–149
98. Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, Mueller G, Wermer M, Kaddurah-Daouk R, Beal MF (1999) Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 5:347–350
99. Choi J, Küstermann E, Dedeoglu A, Jenkins BG (2009) Magnetic resonance spectroscopy of regional brain metabolite markers in FALS mice and the effects of dietary creatine supplementation. Eur J Neurosci 30:2143–2150
100. Derave W, Van Den Bosch L, Lemmens G, Eijnde BO, Robberecht W, Hespel P (2003) Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral sclerosis: effects of creatine treatment. Neurobiol Dis 13:264–272
101. Levkovitch-Verbin H, Waserzoog Y, Vander S, Makarovsky D, Piven I (2014) Minocycline upregulates pro-survival genes and downregulates pro-apoptotic genes in experimental glaucoma. Graefes Arch Clin Exp Ophthalmol 252:761–772
102. Jung C, Rong Y, Doctrow S, Baudry M, Malfroy B, Xu Z (2001) Synthetic superoxide dismutase/catalase mimetics reduce oxidative stress and prolong survival in a mouse amyotrophic lateral sclerosis model. Neurosci Lett 304:157–160
103. Chang Y, Kong Q, Shan X, Tian G, Ilieva H, Cleveland DW, Rothstein JD, Borchelt DR, Wong PC, Lin C-G (2008) Messenger RNA oxidation occurs early in disease pathogenesis and promotes motor neuron degeneration in ALS. PLoS ONE 3
104. Zhang Y, Cook A, Kim J, Baranov SV, Jiang J, Smith K, Cormier K, Bennett E, Browser RP, Day AL, Carlisle DL, Ferrante RJ, Wang X, Friedlander RM (2013) Melatonin inhibits the caspase-1/cytochrome c/caspase-3 cell death pathway, inhibits MT1 receptor loss and delays disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 55:26–35
105. Tokuda E, Okawa E, Watanabe S, Ono S, Marklund SL (2013) Dysregulation of intracellular copper homeostasis is common to transgenic mice expressing human mutant superoxide dismutase-1s regardless of their copper-binding abilities. Neurobiol Dis 54:308–319
106. Song L, Chen L, Zhang X, Li J, Le W (2014) Resveratrol ameliorates motor neuron degeneration and improves survival in SOD1G93A mouse model of amyotrophic lateral sclerosis. BioMed Rese Int 2014
107. Dardiotis E, Panayiotou E, Feldman ML, Hadjisavvas A, Malas S, Vonta I, Hadjigeorgiou G, Kyriakou K, Kyriakides T (2013) Intraperitoneal melatonin is not neuroprotective in the G93ASOD1 transgenic mouse model of familial ALS and may exacerbate neurodegeneration. Neurosci Lett 548:170–175
108. Crow JP, Calingasan NY, Chen J, Hill JL, Beal MF (2005) Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann Neurol 58:258–265
109. Gurney ME, Cutting FB, Zhai P, Doble A, Taylor CP, Andrus PK, Hall ED (1996) Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis. Ann Neurol 39:147–157
110. Snow RJ, Turnbull J, Da Silva S, Jiang F, Tarnopolsky MA (2003) Creatine supplementation and riluzole treatment provide similar beneficial effects in copper, zinc superoxide dismutase (G93A) transgenic mice. Neuroscience 119:661–667
111. Koh J, Kim D, Hwang JY, Kim YH, Seo JH (1999) Antioxidative and proapoptotic effects of riluzole on cultured cortical neurons. J Neurochem 72:716–723
112. http://www.icd10data.com/ICD10CM/Codes/G00-G99/G20-G26/G20-/G20. Accessed 15 May 2015
113. Gandhi SAA (2012) Mechanism of oxidative stress in neurodegeneration. Oxid Med Cell Longev 2012:428010
114. Dexter DT, Carter CJ, Wells FR, Javoy-Agid F, Agid Y, Lees A, Jenner P, Marsden CD (1989) Basal lipid peroxidation in substantia nigra is increased in Parkinson’s disease. J Neurochem 52:381–389
115. Mythri RB, Venkateshappa C, Harish G, Mahadevan A, Muthane UB, Yasha TC, Srinivas Bharath MM, Shankar SK (2011) Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson’s disease brains. Neurochem Res 36:1452–1463
116. Castellani RJ, Perry G, Siedlak SL, Nunomura A, Shimohama S, Zhang J, Montine T, Sayre LM, Smith MA (2002) Hydroxynonenal adducts indicate a role for lipid peroxidation in neocortical and brainstem Lewy bodies in humans. Neurosci Lett 319:25–28
117. Shamoto-Nagai M, Maruyama W, Hashizume Y, Yoshida M, Osawa T, Riederer P, Naoi M (2007) In parkinsonian substantia nigra, a-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. J Neural Transm 114:1559–1567
118. Yoritaka A, Hattori N, Uchida K, Tanaka M, Stadtman ER, Mizuno Y (1996) Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson disease. Proc Natl Acad Sci U S A 93:2696–2701
119. Xiang W, Schlachetzki JCM, Helling S, Bussmann JC, Berlinghof M, Schäffer TE, Marcus K, Winkler J, Klucken J, Becker C (2013) Oxidative stress-induced posttranslational modifications of alpha-synuclein: specific modification of alpha-synuclein by 4-hydroxy-2-nonenal increases dopaminergic toxicity. Mol Cell Neurosci 54:71–83
120. Fessel JP, Hulette C, Powell S, Roberts LJ II, Zhang J (2003) Isofurans, but not F2-isoprostanes, are increased in the substantia nigra of patients with Parkinson’s disease and with dementia with Lewy body disease. J Neurochem 85:645–650
121. Alam ZI, Daniel SE, Lees AJ, Marsden DC, Jenner P, Halliwell B (1997) A generalised increase in protein carbonyls in the brain in Parkinson’s but not incidental Lewy body disease. J Neurochem 69:1326–1329
122. Ogata M, Kaneya D, Shin-Ya K, Li L, Abe Y, Katoh H, Seki S, Seki Y, Gonda R, Urano S, Endo T (2005) Trapping effect of eugenol on hydroxyl radicals induced by L-DOPA in vitro. Chem Pharm Bull 53:1167–1170
123. Good PF, Hsu A, Werner P, Perl DP, Warren Olanow C (1998) Protein nitration in Parkinson’s disease. J Neuropathol Exp Neurol 57:338–342
124. Zhang J, Perry G, Smith MA, Robertson D, Olson SJ, Graham DG, Montine TJ (1999) Parkinson’s disease is associated with oxidative damage to cytoplasmic DNA and RNA in substantia nigra neurons. Am J Pathol 154:1423–1429
125. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B (1997) Oxidative DNA damage in the Parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69:1196–1203
126. Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, Nunomura A, Castellani RJ, Perry G, Smith MA, Itoyama Y (2002) Systemic increase of oxidative nucleic acid damage in Parkinson’s disease and multiple system atrophy. Neurobiol Dis 9:244–248
127. Isobe C, Abe T, Terayama Y (2010) Levels of reduced and oxidized coenzymeQ-10 and 8-hydroxy-2′-deoxyguanosine in the cerebrospinal fluid of patients with living Parkinson’s disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. Neurosci Lett 469:159–163
128. Boll M, Alcaraz-Zubeldia M, Montes S, Rios C (2008) Free copper, ferroxidase and SOD1 activities, lipid peroxidation and NOx content in the CSF. A different marker profile in four neurodegenerative diseases. Neurochem Res 33:1717–1723
129. Selley ML (1998) (E)-4-Hydroxy-2-nonenal may be involved in the pathogenesis of Parkinson’s disease. Free Radic Biol Med 25:169–174
130. Ilic TV, Jovanovic M, Jovicic A, Tomovic M (1999) Oxidative stress indicators are elevated in de novo Parkinson’s disease patients. Funct Neurol 14:141–147
131. Shukla R, Rajani M, Srivastava N, Barthwal MK, Dikshit M (2006) Nitrite and malondialdehyde content in cerebrospinal fluid of patients with Parkinson’s disease. Int J Neurosci 116:1391–1402
132. Sanders LH, Timothy Greenamyre J (2013) Oxidative damage to macromolecules in human Parkinson disease and the rotenone model. Free Radic Biol Med 62:111–120
133. Sato S, Mizuno Y, Hattori N (2005) Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 64:1081–1083
134. Seet RCS, Lee CJ, Lim ECH, Tan JJH, Quek AML, Chong W, Looi W, Huang S, Wang H, Chan Y, Halliwell B (2010) Oxidative damage in Parkinson disease: measurement using accurate biomarkers. Free Radic Biol Med 48:560–566
135. Lee C-J, Seet RCS, Huang SH, Long LH, Halliwell B (2009) Different patterns of oxidized lipid products in plasma and urine of dengue fever, stroke, and Parkinson’s disease patients: cautions in the use of biomarkers of oxidative stress. Antioxid Redox Signal 11:407–420
136. Ahlskog JE, Uitti RJ, Low PA, Tyce GM, Nickander KK, Petersen RC, Kokmen E (1995) No evidence for systemic oxidant stress in Parkinson’s or Alzheimer’s disease. Mov Disord 10:566–573
137. Molina J, Jiménez-Jiménez FJ, Fernandez-Calle P, Lalinde L, Tenias J, Pondal M, Vazquez A, Codoceo R (1992) Serum lipid peroxides in patients with Parkinson’s disease. Neurosci Lett 136:137–140
138. Connolly J, Siderowf A, Clark CM, Mu D, Pratico D (2008) F2 isoprostane levels in plasma and urine do not support increased lipid peroxidation in cognitively impaired parkinson disease patients. Cogn Behav Neurol 21:83–86
139. Sian J, Dexter DT, Lees AJ, Daniel S, Agid Y, Javoy-Agid F, Jenner P, Marsden CD (1994) Alterations in glutathione levels in Parkinson’s disease and other neurodegenerative disorders affecting basal ganglia. Ann Neurol 36:348–355
140. Perry TL, Yong VW (1986) Idiopathic Parkinson’s disease, progressive supranuclear palsy and glutathione metabolism in the substantia nigra of patients. Neurosci Lett 67:269–274
141. Perry TL, Godin DV, Hansen S (1982) Parkinson’s disease: a disorder due to nigral glutathione deficiency? Neurosci Lett 33:305–310
142. Danielson SR, Andersen JK (2008) Oxidative and nitrative protein modifications in Parkinson’s disease. Free Radic Biol Med 44:1787–1794
143. Riederer P, Sofic E, Rausch W, Schmidt B, Reynolds GP, Jellinger K, Youdim MBH (1989) Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem 52:515–520
144. Chinta SJ, Andersen JK (2008) Redox imbalance in Parkinson’s disease. Biochim Biophys Acta Gen Subj 1780:1362–1367
145. Marttila RJ, Lorentz H, Rinne UK (1988) Oxygen toxicity protecting enzymes in Parkinson’s disease: increase of superoxide dismutase-like activity in the substantia nigra and basal nucleus. J Neurol Sci 86:321–331
146. Kish SJ, Morito C, Hornykiewicz O (1985) Glutathione peroxidase activity in Parkinson’s disease brain. Neurosci Lett 58:343–346
147. Mbangata MB, Kartha RV, Mishra U, Coles LD, Tuite PJ, Cloyd JC (2014) Oxidative stress status in patients with Parkinson’s disease on and off medication. Mov Disord 29:S143
148. Sechi G, Deledda MG, Bua G, Satta WM, Deiana GA, Pes GM, Rosati G (1996) Reduced intravenous glutathione in the treatment of early Parkinson’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry 20:1159–1170
149. Holmay MJ, Terpstra M, Coles LD, Mishra U, Ahlskog M, Öz G, Cloyd JC, Tuite PJ (2013) N-acetylcysteine boosts brain and blood glutathione in gaucher and Parkinson diseases. Clin Neuropharmacol 36:103–106
150. Katz M, Swanson RA, Glass GA (2014) Cerebrospinal fluid concentrations of N-acetylcysteine after oral administration: phase I trial in Parkinson’s disease. Mov Disord 29:S247
151. Gorell JM, Ordidge RJ, Brown GG, Deniau J, Buderer NM, Helpern JA (1995) Increased iron-related MRI contrast in the substantia nigra in Parkinson’s disease. Neurology 45:1138–1143
152. Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garçon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonnière B, Strubi-Vuillaume I, Zahr N, Destée A, Corvol J, Pöltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R (2014) Targeting chelatable iron as a therapeutic modality in Parkinson’s disease. Antioxid Redox Signal 21:195–210
153. Shoulson I (1998) DATATOP: a decade of neuroprotective inquiry. Ann Neurol 44:S160–S166
154. Shoulson I, Fahn S, Oakes D, Kieburtz K, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Rudolph A, Pelusio RM (1993) Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N Engl J Med 328:176–183
155. Beal MF (2014) A randomized clinical trial of high-dosage coenzyme q10 in early parkinson disease no evidence of benefit. JAMA Neurol 71:543–552
156. Su W, Chen H, Zhang Z, Chen B, Wang L, Sun X, Shen Y, Li Y, Geng T, Zhao W, Zhang X (2004) A multi-center, randomized, vitamin E controlled and opening clinical trial of selegiline in patients with Parkinson’s disease. Chin J Neurol 37:413–416
157. Shults CW, Oakes D, Kieburtz K, Flint Beal M, Haas R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M (2002) Effects of coenzyme Q 10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 59:1541–1550
158. Storch A, Jost WH, Vieregge P, Spiegel J, Greulich W, Durner J, MüLler T, Kupsch A, Henningsen H, Oertel WH, Fuchs G, Kuhn W, Niklowitz P, Koch R, Herting B, Reichmann H (2007) Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. Arch Neurol 64:938–944
159. NINDS (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66:664–671
160. Kieburtz K, Tilley B, Ravina B, Galpern W, Shannon K, Tanner C, Wooten GF (2008) A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results. Clin Neuropharmacol 31:141–150
161. Bender A, Koch W, Elstner M, Schombacher Y, Bender J, Moeschl M, Gekeler F, Muller-Myhsok B, Gasser T, Tatsch K, Klopstock T (2006) Creatine supplementation in Parkinson disease: a placebo-controlled randomized pilot trial. Neurology 67:1262–1264
162. http://parkinsontrial.ninds.nih.gov/netpd-LS1-study-termination.htm. Accessed 15 May 2015
163. Hirayama M, Goto S, Nakamura T, Mizutani Y, Suzuki J, Watanabe H, Sobue G (2014) Oxdative stress maker (urinary 8-hydroxy-2′-deoxyguanosine) was modified by treatment of various Parkinson’s drug. Mov Disord 29:S140
164. Sen CK (1999) Glutathione homeostasis in response to exercise training and nutritional supplements. Mol Cell Biochem 196:31–42
165. Elokda A, Di Francisco-Donoghue J, Lamberg EM, Werner WG (2010) Effects of exercise induced oxidative stress on glutathione levels in Parkinson’s disease on and off medication. J Neurol 257:1648–1653
166. Nikolova GD, Grigorov BG, Zheleva AM, Gadjeva VG (2014) Influence of therapy on some important final products of oxidation of lipids, proteins and nucleic acids in patients with Parkinson’s diseases. Adv Biol Chem 4:253–260
167. Blesa J, Phani S, Jackson-Lewis V, Przedborski S (2012) Classic and new animal models of Parkinson’s disease. J Biomed Biotechnol 2012
168. Ungerstedt U (1971) Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scandinav, Suppl 367:69–93
169. Langston JW, Forno LS, Rebert CS, Irwin I (1984) Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res 292:390–394
170. Blesa J, Juri C, Collantes M, Peñuelas I, Prieto E, Iglesias E, Martí-Climent J, Arbizu J, Zubieta JL, Rodríguez-Oroz MC, García-García D, Richter JA, Cavada C, Obeso JA (2010) Progression of dopaminergic depletion in a model of MPTP-induced parkinsonism in non-human primates. An 18F-DOPA and 11C-DTBZ PET study. Neurobiol Dis 38:456–463
171. Ohashi S1, Mori A, Kurihara N, Mitsumoto Y, Nakai M (2006) Age-related severity of dopaminergic neurodegeneration to MPTP neurotoxicity causes motor dysfunction in C57BL/6 mice. Neurosci Lett 401(1–2):183–187 (2006 Jun 19;401(1–2):183–7. Epub 2006 Apr 3.)
172. Shimohama S, Hisahara S (2011) Toxin-induced and genetic animal models of Parkinson’s disease. Parkinson’s Dis
173. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson’s disease. Nat Neurosci 3:1301–1306
174. McCormack AL, Atienza JG, Johnston LC, Andersen JK, Vu S, Di Monte DA (2005) Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J Neurochem 93:1030–1037
175. Kumar A, Leinisch F, Kadiiska MB, Corbett J, Mason RP (2015) Formation and implications of alpha-synuclein radical in maneb- and paraquat-induced models of Parkinson’s disease. Mol Neurobiol
176. Smith MP, Cass WA (2007) Oxidative stress and dopamine depletion in an intrastriatal 6-hydroxydopamine model of Parkinson’s disease. Neuroscience 144:1057–1066
177. Haleagrahara N, Siew CJ, Ponnusamy K (2013) Effect of quercetin and desferrioxamine on 6-hydroxydopamine (6-OHDA) induced neurotoxicity in striatum of rats. J Toxicol Sci 38:25–33
178. Dagdelen M, Akkaya H, Genc E (2013) The role of valproic acid and levodopa on oxidative stress in a 6-hydroxydopamine lesioned rat model of Parkinson’s disease. Eur Neuropsychopharmacol 23:S197
179. Inden M, Kitamura Y, Kondo J, Hayashi K, Yanagida T, Takata K, Tsuchiya D, Yanagisawa D, Nishimura K, Taniguchi T, Shimohama S, Sugimoto H, Akaike A (2005) Serofendic acid prevents 6-hydroxydopamine-induced nigral neurodegeneration and drug-induced rotational asymmetry in hemi-parkinsonian rats. J Neurochem 95:950–961
180. Su-Fen Y, Zheng-Qin Y, Qin W, An-Sheng S, Xie-Nan H, Jing-Shan S (2001) Protective effect and mechanism of Ginkgo biloba leaf extracts for Parkinson disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Acta Pharmacol Sin 22:1089–1093
181. Ghosh A, Kanthasamy A, Joseph J, Anantharam V, Srivastava P, Dranka BP, Kalyanaraman B, Kanthasamy AG (2012) Anti-inflammatory and neuroprotective effects of an orally active apocynin derivative in pre-clinical models of Parkinson’s disease. J Neuroinflammat 9
182. Bisht R, Kaur B, Gupta H, Prakash A (2014) Ceftriaxone mediated rescue of nigral oxidative damage and motor deficits in MPTP model of Parkinson’s disease in rats. Neurotoxicology 44:71–79
183. Barbiero JK, Santiago R, Tonin FS, Boschen S, da Silva LM, de Paula Werner MF, da Cunha C, Lima MMS, Vital MABF (2014) PPAR-α agonist fenofibrate protects against the damaging effects of MPTP in a rat model of Parkinson’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry 53:35–44
184. Verma R, Nehru B (2009) Effect of centrophenoxine against rotenone-induced oxidative stress in an animal model of Parkinson’s disease. Neurochem Int 55:369–375
185. Zaitone SA, Abo-Elmatty DM, Shaalan AA (2012) Acetyl-l-carnitine and (alpha)-lipoic acid affect rotenone-induced damage in nigral dopaminergic neurons of rat brain, implication for Parkinson’s disease therapy. Pharmacol Biochem Behav 100:347–360
186. Gokul K, Muralidhara (2014) Oral supplements of aqueous extract of tomato seeds alleviate motor abnormality, oxidative impairments and neurotoxicity induced by rotenone in mice: relevance to Parkinson’s disease. Neurochem Res 39:1382–1394
187. Liang L, Huang J, Fulton R, Day BJ, Patel M (2007) An orally active catalytic metalloporphyrin protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine neurotoxicity in vivo. J Neurosci 27:4326–4333
188. Chen L, Gao Y, Li X, Shen D, Sun F (2005) Melatonin protects against MPTP/MPP+-induced mitochondrial DNA oxidative damage in vivo and in vitro. J Pineal Res 39:34–42
189. Fujita K, Seike T, Yutsudo N, Ohno M, Yamada H, Yamaguchi H, Sakumi K, Yamakawa Y, Kido MA, Takaki A, Katafuchi T, Tanaka Y, Nakabeppu Y, Noda M (2009) Hydrogen in drinking water reduces dopaminergic neuronal loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. PLoS ONE 4
190. Singhal NK, Srivastava G, Patel DK, Jain SK, Singh MP (2011) Melatonin or silymarin reduces maneb- and paraquat-induced Parkinson’s disease phenotype in the mouse. J Pineal Res 50:97–109
191. Ahmad M, Saleem S, Ahmad AS, Yousuf S, Ansari MA, Khan MB, Ishrat T, Chaturvedi RK, Agrawal AK, Islam F (2005) Ginkgo biloba affords dose-dependent protection against 6-hydroxydopamine-induced parkinsonism in rats: neurobehavioural, neurochemical and immunohistochemical evidences. J Neurochem 93:94–104
192. Thomas B, Mohanakumar KP (2004) Melatonin protects against oxidative stress caused by 1-methyl-4-phenyl-1, 2,3,6-tetrahydropyridine in the mouse nigrostriatum. J Pineal Res 36:25–32
193. Zaminelli T, Gradowski RW, Bassani TB, Barbiero JK, Santiago RM, Maria-Ferreira D, Baggio CH, Vital MABF (2014) Antidepressant and antioxidative effect of ibuprofen in the rotenone model of Parkinson’s disease. Neurotoxicity Res
194. Karuppagounder SS, Madathil SK, Pandey M, Haobam R, Rajamma U, Mohanakumar KP (2013) Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson’s disease in rats. Neuroscience 236:136–148
195. Kaur H, Chauhan S, Sandhir R (2011) Protective effect of lycopene on oxidative stress and cognitive decline in rotenone induced model of Parkinson’s disease. Neurochem Res 36:1435–1443
196. Khurana N, Gajbhiye A (2013) Ameliorative effect of Sida cordifolia in rotenone induced oxidative stress model of Parkinson’s disease. Neurotoxicology 39:57–64
197. Chen C, Yin M, Hsu C, Liu T (2007) Antioxidative and anti-inflammatory effects of four cysteine-containing agents in striatum of MPTP-treated mice. Nutrition 23:589–597
198. Kaya Y, Ozsoy O, Onullut E, Aslan M, Yildirim FB, Anullar A (2013) Beneficial effect of melatonin treatment on substantia nigra in an experimental model of Parkinson’s disease. J Neurol Sci 30:142
199. Sharma A, Kaur P, Kumar V, Gill KD (2007) Attenuation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced nigrostriatal toxicity in mice by N-acetyl cysteine. Cell Mol Biol 53:48–55
200. Shin JY, Park H, Ahn YH, Lee PH (2009) Neuroprotective effect of l-dopa on dopaminergic neurons is comparable to pramipexol in MPTP-treated animal model of Parkinson’s disease: a direct comparison study. J Neurochem 111:1042–1050
201. Sutherland GT, Chami B, Youssef P, Witting PK (2013) Oxidative stress in Alzheimer’s disease: primary villain or physiological by-product? Redox Rep 18:134–141
202. Wolfson C, Wolfson DB, Asgharian M, M’Lan CE, Østbye T, Rockwood K, Hogan DB (2001) A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 344:1111–1116
203. Martins RN, Harper CG, Stokes GB, Masters CL (1986) Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer’s disease may reflect oxidative stress. J Neurochem 46:1042–1045
204. Sultana R, Butterfield DA (2010) Role of oxidative stress in the progression of Alzheimer’s disease. J Alzheimer’s Dis 19:341–353
205. Ansari MA, Scheff SW (2010) Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J Neuropathol Exp Neurol 69:155–167
206. Lüth H, Münch G, Arendt T (2002) Aberrant expression of NOS isoforms in Alzheimer’s disease is structurally related to nitrotyrosine formation. Brain Res 953:135–143
207. Lüth H, Holzer M, Gärtner U, Staufenbiel M, Arendt T (2001) Expression of endothelial and inducible NOS-isoforms is increased in Alzheimer’s disease, in APP23 transgenic mice and after experimental brain lesion in rat: evidence for an induction by amyloid pathology. Brain Res 913:57–67
208. Massaad CA (2011) Neuronal and vascular oxidative stress in Alzheimer’s disease. Curr Neuropharmacol 9:662–673
209. Toda N, Ayajiki K, Okamura T (2009) Cerebral blood flow regulation by nitric oxide in neurological disorders. Can J Physiol Pharmacol 87:581–594
210. Lovell MA, Gabbita SP, Markesbery WR (1999) Increased DNA oxidation and decreased levels of repair products in Alzheimer’s disease ventricular CSF. J Neurochem 72:771–776
211. Mecocci P, MacGarvey U, Beal MF (1994) Oxidative damage to mitochondrial DNA is increased in Alzheimer’s disease. Ann Neurol 36:747–751
212. Lovell MA, Xie C, Markesbery WR (1998) Decreased glutathione transferase activity in brain and ventricular fluid in Alzheimer’s disease. Neurology 51:1562–1566
213. Casado Á, Encarnación López-Fernández M, Concepción Casado M, De La Torre R (2008) Lipid peroxidation and antioxidant enzyme activities in vascular and Alzheimer dementias. Neurochem Res 33:450–458
214. Marcus DL, Thomas C, Rodriguez C, Simberkoff K, Tsai JS, Strafaci JA, Freedman ML (1998) Increased peroxidation and reduced antioxidant enzyme activity in Alzheimer’s disease. Exp Neurol 150:40–44
215. Spalletta G, Bernardini S, Bellincampi L, Federici G, Trequattrini A, Ciappi F, Bria P, Caltagirone C, Bossù P (2007) Glutathione S-transferase p1 and t1 gene polymorphisms predict longitudinal course and age at onset of Alzheimer disease. Am J Geriatr Psychiatr 15:879–887
216. Paz-Y-Miño C, Carrera C, López-Cortés A, Muñoz MJ, Cumbal N, Castro B, Cabrera A, Sánchez ME (2010) Genetic polymorphisms in apolipoprotein e and glutathione peroxidase 1 genes in the Ecuadorian population affected with Alzheimer’s disease. Am J Med Sci 340:373–377
217. Aoyama K, Nakaki T (2013) Impaired glutathione synthesis in neurodegeneration. Int J Mol Sci 14:21021–21044
218. Sultana R, Piroddi M, Galli F, Butterfield DA (2008) Protein levels and activity of some antioxidant enzymes in hippocampus of subjects with amnestic mild cognitive impairment. Neurochem Res 33:2540–2546
219. Foy CJ, Passmore AP, Vahidassr MD, Young IS, Lawson JT (1999) Plasma chain-breaking antioxidants in Alzheimer’s disease, vascular dementia and Parkinson’s disease. QJM - Month J Assoc Phys 92:39–45
220. Kim T, Pae C, Yoon S, Jang W, Lee NJ, Kim J, Lee S, Lee C, Paik I, Lee C (2006) Decreased plasma antioxidants in patients with Alzheimer’s disease. Int J Geriatr Psychiatr 21:344–348
221. Giavarotti L, Simon KA, Azzalis LA, Fonseca FLA, Lima AF, Freitas MCV, Brunialti MKC, Salomão R, Moscardi AAVS, M. Montaño MBM, Ramos LR, Junqueira VBC (2013) Mild systemic oxidative stress in the subclinical stage of Alzheimer’s disease. Oxidat Med Cell Longevity
222. Arlt S, Müller-Thomsen T, Beisiegel U, Kontush A (2012) Effect of one-year vitamin C- and E-supplementation on cerebrospinal fluid oxidation parameters and clinical course in Alzheimer’s disease. Neurochem Res 37:2706–2714
223. Galasko DR, Peskind E, Clark CM, Quinn JF, Ringman JM, Jicha GA, Cotman C, Cottrell B, Montine TJ, Thomas RG, Aisen P (2012) Antioxidants for Alzheimer disease: a randomized clinical trial with cerebrospinal fluid biomarker measures. Arch Neurol 69:836–841
224. Dysken MW, Sano M, Asthana S, Vertrees JE, Pallaki M, Llorente M, Love S, Schellenberg GD, McCarten JR, Malphurs J, Prieto S, Chen P, Loreck DJ, Trapp G, Bakshi RS, Mintzer JE, Heidebrink JL, Vidal-Cardona A, Arroyo LM, Cruz AR, Zachariah S, Kowall NW, Chopra MP, Craft S, Thielke S, Turvey CL, Woodman C, Monnell KA, Gordon K, Tomaska J, Segal Y, Peduzzi PN, Guarino PD (2014) Effect of vitamin E and memantine on functional decline in Alzheimer disease: the TEAM-AD VA cooperative randomized trial. JAMA - J Am Med Assoc 311:33–44
225. Thal LJ, Grundman M, Berg J, Ernstrom K, Margolin R, Pfeiffer E, Weiner MF, Zamrini E, Thomas RG (2003) Idebenone treatment fails to slow cognitive decline in Alzheimer’s disease. Neurology 61:1498–1502
226. Quinn JF, Raman R, Thomas RG, Yurko-Mauro K, Nelson EB, Van Dyck C, Galvin JE, Emond J, Jack CR Jr, Weiner M, Shinto L, Aisen PS (2010) Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial. JAMA - J Am Med Assoc 304:1903–1911
227. Freund-Levi Y, Eriksdotter-Jönhagen M, Cederholm T, Basun H, Faxén-Irving G, Garlind A, Vedin I, Vessby B, Wahlund L, Palmblad J (2006) ω-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study—a randomized double-blind trial. Arch Neurol 63:1402–1408
228. Shinto L, Quinn J, Montine T, Dodge HH, Woodward W, Baldauf-Wagner S, Waichunas D, Bumgarner L, Bourdette D, Silbert L, Kaye J (2014) A randomized placebo-controlled pilot trial of omega-3 fatty acids and alpha lipoic acid in Alzheimer’s disease. J Alzheimer’s Dis 38:111–120
229. Ringman JM, Frautschy SA, Teng E, Begum AN, Bardens J, Beigi M, Gylys KH, Badmaev V, Heath DD, Apostolova LG, Porter V, Vanek Z, Marshall GA, Hellemann G, Sugar C, Masterman DL, Montine TJ, Cummings JL, Cole GM (2012) Oral curcumin for Alzheimer’s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study. Alzheimer’s Res Therapy 4
230. Baum L, Lam CWK, Cheung SK, Kwok T, Lui V, Tsoh J, Lam L, Leung V, Hui E, Ng C, Woo J, Chiu HFK, Goggins WB, Zee BC, Cheng KF, Fong CYS, Wong A, Mok H, Chow MSS, Ho PC, Ip SP, Ho CS, Yu XW, Lai CYL, Chan M, Szeto S, Chan IHS, Mok V (2008) Six-month randomized, placebo-controlled, double-blind, pilot clinical trial of curcumin in patients with Alzheimer disease. J Clin Psychopharmacol 28:110–113
231. Disilvestro RA, Joseph E, Zhao S, Bomser J (2012) Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutrition J 11
232. Truelsen T, Thudium D, Grønbæk M (2002) Amount and type of alcohol and risk of dementia: the Copenhagen City Heart Study. Neurology 59:1313–1319
233. https://clinicaltrials.gov/ct2/show/NCT01504854. Accessed 15 May 2015
234. Klugman A, Naughton DP, Isaac M, Shah I, Petroczi A, Tabet N (2012) Antioxidant enzymatic activities in Alzheimer’s disease: the relationship to acetylcholinesterase inhibitors. J Alzheimer’s Dis 30:467–474
235. Gubandru M, Margina D, Tsitsimpikou C, Goutzourelas N, Tsarouhas K, Ilie M, Tsatsakis AM, Kouretas D (2013) Alzheimer’s disease treated patients showed different patterns for oxidative stress and inflammation markers. Food Chem Toxicol 61:209–214
236. Snalina N, Alessenko A, Gavrilova S, Gurianova S, Prochorov A, Kononova E, Fedorova Y (2014) Memantine changes lipids spectrum and lipid peroxidation in animal brain and plasma of patients with Alzheimer’s disease. FEBS J 281:86
237. Hu D, Li C, Han N, Miao L, Wang D, Liu Z, Wang H, Yin J (2012) Deoxyschizandrin isolated from the fruits of Schisandra chinensis ameliorates a ß induced memory impairment in mice. Planta Med 78:1332–1336
238. Hou X, Wu D, Zhang C, Yan R, Yang C, Rong C, Zhang L, Chang X, Su R, Zhang S, He W, Qu Z, Li S, Su Z, Chen Y, Wang Q, Fang S (2014) Bushen-Yizhi formula ameliorates cognition deficits and attenuates oxidative stress-related neuronal apoptosis in scopolamine-induced senescence in mice. Int J Mol Med 34:429–439
239. Chonpathompikunlert P, Wattanathorn J, Muchimapura S (2010) Piperine, the main alkaloid of Thai black pepper, protects against neurodegeneration and cognitive impairment in animal model of cognitive deficit like condition of Alzheimer’s disease. Food Chem Toxicol 48:798–802
240. Veerendra Kumar MH, Gupta YK (2003) Effect of Centella asiatica on cognition and oxidative stress in an intracerebroventricular streptozotocin model of Alzheimer’s disease in rats. Clin Exp Pharmacol Physiol 30:336–342
241. Li X, Zhao X, Xu X, Mao X, Liu Z, Li H, Guo L, Bi K, Jia Y (2014) Schisantherin A recovers A(beta)-induced neurodegeneration with cognitive decline in mice. Physiol Behav 132:10–16
242. Fan Y, Hu J, Li J, Yang Z, Xin X, Wang J, Ding J, Geng M (2005) Effect of acidic oligosaccharide sugar chain on scopolamine-induced memory impairment in rats and its related mechanisms. Neurosci Lett 374:222–226
243. Richards JG, Higgins GA, Ouagazzal A, Ozmen L, Kew JNC, Bohrmann B, Malherbe P, Brockhaus M, Loetscher H, Czech C, Huber G, Bluethmann H, Jacobsen H, Kemp JA (2003) PS2APP transgenic mice, coexpressing hPS2mut and hAPPswe, show age-related cognitive deficits associated with discrete brain amyloid deposition and inflammation. J Neurosci 23:8989–9003
244. Cavanaugh SE, Pippin JJ, Barnard ND (2014) Animal models of Alzheimer disease: historical pitfalls and a path forward. ALTEX 31:279–302
245. Götz J, Ittner LM (2008) Animal models of Alzheimer’s disease and frontotemporal dementia. Nat Rev Neurosci 9:532–544
246. Lannert H, Hoyer S (1998) Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 112:1199–1208
247. Jhoo JH, Kim H, Nabeshima T, Yamada K, Shin E, Jhoo W, Kim W, Kang K, Jo SA, Woo JI (2004) β-Amyloid (1–42)-induced learning and memory deficits in mice: involvement of oxidative burdens in the hippocampus and cerebral cortex. Behav Brain Res 155:185–196
248. Budzynska B, Boguszewska-Czubara A, Kruk-Slomka M, Skalicka-Wozniak K, Michalak A, Musik I, Biala G (2015) Effects of imperatorin on scopolamine-induced cognitive impairment and oxidative stress in mice. Psychopharmacology (Berl) 232:931–942
249. Goverdhan P, Sravanthi A, Mamatha T (2012) Neuroprotective effects of meloxicam and selegiline in scopolamine-induced cognitive impairment and oxidative stress. Int J Alzheimer’s Dis
250. Javed H, Khan MM, Khan A, Vaibhav K, Ahmad A, Khuwaja G, Ahmed ME, Raza SS, Ashafaq M, Tabassum R, Siddiqui MS, El-Agnaf OM, Safhi MM, Islam F (2011) S-allyl cysteine attenuates oxidative stress associated cognitive impairment and neurodegeneration in mouse model of streptozotocin-induced experimental dementia of Alzheimer’s type. Brain Res 1389:133–142
251. Siedlak SL, Casadesus G, Webber KM, Pappolla MA, Atwood CS, Smith MA, Perry G (2009) Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer’s disease. Free Radic Res 43:156–164
252. Harrison FE, Hosseini AH, McDonald MP, May JM (2009) Vitamin C reduces spatial learning deficits in middle-aged and very old APP/PSEN1 transgenic and wild-type mice. Pharmacol Biochem Behav 93:443–450
253. Hartl D, Schuldt V, Forler S, Zabel C, Klose J, Rohe M (2012) Presymptomatic alterations in energy metabolism and oxidative stress in the APP23 mouse model of Alzheimer disease. J Proteome Res 11:3295–3304
254. Feng Z, Qin C, Chang Y, Zhang J (2006) Early melatonin supplementation alleviates oxidative stress in a transgenic mouse model of Alzheimer’s disease. Free Radic Biol Med 40:101–109
255. Zhang W, Bai M, Xi Y, Hao J, Liu L, Mao N, Su C, Miao J, Li Z (2012) Early memory deficits precede plaque deposition in APPswe/PS1dE9 mice: involvement of oxidative stress and cholinergic dysfunction. Free Radic Biol Med 52:1443–1452
256. Khan MB, Khan MM, Khan A, Ahmed ME, Ishrat T, Tabassum R, Vaibhav K, Ahmad A, Islam F (2012) Naringenin ameliorates Alzheimer’s disease (AD)-type neurodegeneration with cognitive impairment (AD-TNDCI) caused by the intracerebroventricular-streptozotocin in rat model. Neurochem Int 61:1081–1093
257. Harrison FE, May JM, McDonald MP (2010) Vitamin C deficiency increases basal exploratory activity but decreases scopolamine-induced activity in APP/PSEN1 transgenic mice. Pharmacol Biochem Behav 94:543–552
258. Duffy AM, Hölscher C (2013) The incretin analogue D-Ala2GIP reduces plaque load, astrogliosis and oxidative stress in an APP/PS1 mouse model of Alzheimer’s disease. Neuroscience 228:294–300
259. Wang D, Liu L, Zhu X, Wu W, Wang Y (2014) Hesperidin alleviates cognitive impairment, mitochondrial dysfunction and oxidative stress in a mouse model of Alzheimer’s disease. Cell Mol Neurobiol
260. Otalora BB, Popovic N, Gambini J, Popovic M, Viña J, Bonet-Costa V, Reiter RJ, Camello PJ, Rol MÁ, Madrid JA (2012) Circadian system functionality, hippocampal oxidative stress, and spatial memory in the APPswePS1dE9 transgenic model of Alzheimer disease: effects of melatonin or ramelteon. Chronobiol Int 29:822–834
261. Saxena G, Singh SP, Agrawal R, Nath C (2008) Effect of donepezil and tacrine on oxidative stress in intracerebral streptozotocin-induced model of dementia in mice. Eur J Pharmacol 581:283–289
262. Benzie IFF, Strain JJ (1996) The ferric reducing ability of plasma (FRAP) as a measure of ‘antioxidant power’: the FRAP assay. Anal Biochem 239:70–76
263. Kracmarova A, Bandouchova H, Pikula J, Pohanka M (2012) Tacrine is implicated in oxidative stress in the laboratory guinea pig model. Neuroendocrinol Lett 33:136–144
264. Khurana S, Jain S, Mediratta PK, Banerjee BD, Sharma KK (2012) Protective role of curcumin on colchicine-induced cognitive dysfunction and oxidative stress in rats. Hum Exp Toxicol 31:686–697
265. Mahdy K, Shaker O, Wafay H, Nassar Y, Hassan H, Hussein A (2012) Effect of some medicinal plant extracts on the oxidative stress status in Alzheimer’s disease induced in rats. Eur Rev Med Pharmacol Sci 16:31–42
266. Kumar A, Prakash A, Pahwa D (2011) Galantamine potentiates the protective effect of rofecoxib and caffeic acid against intrahippocampal kainic acid-induced cognitive dysfunction in rat. Brain Res Bull 85:158–168
267. Pietá Dias C, Martins de Lima MN, Presti-Torres J, Dornelles A, Garcia VA, Siciliani Scalco F, Rewsaat Guimarães M, Constantino L, Budni P, Dal-Pizzol F, Schröder N (2007) Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats. Neuroscience 146:1719–1725
268. Arif M, Chikuma T, Ahmed MM, Nakazato M, Smith MA, Kato T (2009) Effects of memantine on soluble Αβ25-35-induced changes in peptidergic and glial cells in Alzheimer’s disease model rat brain regions. Neuroscience 164:1199–1209
269. Rai S, Kamat PK, Nath C, Shukla R (2014) Glial activation and post-synaptic neurotoxicity: the key events in streptozotocin (ICV) induced memory impairment in rats. Pharmacol Biochem Behav 117:104–117
270. Kamat PK, Tota S, Saxena G, Shukla R, Nath C (2010) Okadaic acid (ICV) induced memory impairment in rats: a suitable experimental model to test anti-dementia activity. Brain Res 1309:66–74
271. Nasr P, Carbery T, Geddes JW (2009) N-Methyl-D-aspartate receptor antagonists have variable affect in 3-nitropropionic acid toxicity. Neurochem Res 34:490–498
272. Rojas JC, Saavedra JA, Gonzalez-Lima F (2008) Neuroprotective effects of memantine in a mouse model of retinal degeneration induced by rotenone. Brain Res 1215:208–217
273. Zaja-Milatovic S, Gupta RC, Aschner M, Milatovic D (2009) Protection of DFP-induced oxidative damage and neurodegeneration by antioxidants and NMDA receptor antagonist. Toxicol Appl Pharmacol 240:124–131
274. Lü J, Lin PH, Yao Q, Chen C (2010) Chemical and molecular mechanisms of antioxidants: experimental approaches and model systems. J Cell Mol Med 14:840–860
275. Rahal A, Kumar A, Singh V, Yadav B, Tiwari R, Chakraborty S, Dhama K (2014) Oxidative stress, prooxidants, and antioxidants: the interplay. BioMed Res Int 2014
276. Townsend DM, Tew KD (2003) The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22:7369–7375
277. Tabart J, Kevers C, Pincemail J, Defraigne J, Dommes J (2009) Comparative antioxidant capacities of phenolic compounds measured by various tests. Food Chem 113:1226–1233
278. Siasos G, Tousoulis D, Tsigkou V, Kokkou E, Oikonomou E, Vavuranakis M, Basdra EK, Papavassiliou AG, Stefanadis C (2013) Flavonoids in atherosclerosis: an overview of their mechanisms of action. Curr Med Chem 20:2641–2660
279. Jomova K, Valko M (2011) Advances in metal-induced oxidative stress and human disease. Toxicology 283:65–87
280. Lushchak VI (2012) Glutathione homeostasis and functions: potential targets for medical interventions. J Amino Acids 2012
281. Djamali A (2007) Oxidative stress as a common pathway to chronic tubulointerstitial injury in kidney allografts. Am J Physiol - Renal Physiol
282. Bartosz G (2009) Reactive oxygen species: destroyers or messengers? Biochem Pharmacol 77:1303–1315
283. Brieger K, Schiavone S, Miller FJ, Krause K- (2012) Reactive oxygen species: from health to disease. Swiss Medical Weekly 142